ReviewMolecules (Basel, Switzerland)2020
Recent Advances in the Chemical Synthesis and Evaluation of Anticancer Nucleoside Analogues.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Systems metabolic engineering of a plasmid-freeSynthetic and systems biotechnology · 2027Article
- Identification of Antileukemic Compound From Ginger by Integrating UHPLC-MS, Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and In Vitro and In Vivo Experimental Validation.Food science & nutrition · 2026Article
- AnOrganic letters · 2026Article
- Preclinical Investigation of PLGA Nanocapsules and Nanostructured Lipid Carriers for Organoselenium Delivery: Comparative In Vitro Toxicological Profile and Anticancer Insights.Pharmaceutics · 2025Article
- Direct and efficient synthesis of nucleosides through the ortho-(tert-butylethynyl)phenyl thioglycosides (BEPTs) protocol.Nature communications · 2025Article
- Abacavir enhances the efficacy of doxorubicin via inhibition of histone demethylase KDM5B in breast cancer.Scientific reports · 2025Article
- Unraveling resistance mechanisms to the novel nucleoside analog RX-3117 in lung cancer: insights into DNA repair, cell cycle dysregulation and targeting PKMYT1 for improved therapy.Journal of experimental & clinical cancer research : CR · 2025Article
- 3'-RSC chemical biology · 2025Article
- Unveiling Palmitoyl Thymidine Derivatives as Antimicrobial/Antiviral Inhibitors: Synthesis, Molecular Docking, Dynamic Simulations, ADMET, and Assessment of Protein-Ligand Interactions.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Synthesis, Antiproliferative Activity, and ADME Profiling of Novel Racemic and Optically Pure Aryl-Substituted Purines and Purine Bioisosteres.Biomolecules · 2025Article
- Unmasking the halide effect in diastereoselective Grignard reactions applied to C4´ modified nucleoside synthesis.Nature communications · 2025Article
- Synthesis, HScientific reports · 2025Article
- Microwave-assisted synthesis of base-modified fluorescent 1,4-dihydropyridine nucleosides: photophysical characterization and insights.RSC advances · 2024Article
- Synthesis of Nucleoside Analogs Containing Sulfur or Selenium Replacements of the Ribose Ring Oxygen or Carbon.The Journal of organic chemistry · 2024Review
- Recent Advances in the Synthesis of Acyclic Nucleosides and Their Therapeutic Applications.Topics in current chemistry (Cham) · 2024Review
- Exploring the Mutated Kinases for Chemoenzymatic Synthesis ofMolecules (Basel, Switzerland) · 2024Article
- Induction of Apoptotic Signaling Pathways by 3' methyl ATP in Different Malignant Cells: in vitro Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Article
- Evaluation of Anticancer Activity of Nucleoside-Nitric Oxide Photo-Donor Hybrids.Molecules (Basel, Switzerland) · 2024Article
- Purine nucleoside antibiotics: recent synthetic advances harnessing chemistry and biology.Natural product reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleoside analogues have proven to be highly successful chemotherapeutic agents in the treatment of a wide variety of cancers. Several such compounds, including gemcitabine and cytarabine, are the go-to option in first-line treatments. However, these materials do have limitations and the development of next generation compounds remains a topic of significant interest and necessity. Herein, we discuss recent advances in the chemical synthesis and biological evaluation of nucleoside analogues as potential anticancer agents. Focus is paid to 4'-heteroatom substitution of the furanose oxygen, 2'-, 3'-, 4'- and 5'-position ring modifications and the development of new prodrug strategies for these materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.